newsfilter
← Latest News
GlobeNewswire·

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

  • MapLight Therapeutics initiated start-up activities for ZEPHYR-2, a Phase 3 confirmatory trial of ML-007C-MA in schizophrenia, with topline results expected in 2028.
  • Enrollment continues in the Phase 2 VISTA trial for ML-007C-MA in Alzheimer's disease psychosis, with topline results anticipated in the second half of 2027.
  • ML-007C-MA holds FDA Fast Track designation for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis.
  • The company ended the third quarter of 2026 with $463.4 million in cash, cash equivalents, and investments, expected to fund operations through 2028.
  • ML-007C-MA met its primary endpoint in the Phase 2 ZEPHYR trial, demonstrating statistically significant reduction in PANSS total scores with a favorable tolerability profile.
  • The company plans to engage the FDA in an End-of-Phase 2 meeting to discuss the registrational path for ML-004 in autism spectrum disorder following positive Phase 2 IRIS trial results.
  • A $150 million private placement completed in August 2026 will support the advancement of ML-007C-MA programs and general corporate purposes.
  • Research and development expenses for the third quarter of 2026 were $44.2 million, while general and administrative expenses were $11.1 million.
  • The company reported a net loss of $51.6 million for the third quarter of 2026, compared to $29.4 million in the same period of 2025.
  • MapLight Therapeutics is pausing significant investment in preclinical programs to focus resources on ML-007C-MA and ML-004 milestones.
Company
MapLight Therapeutics, Inc.
Keywords
Nasdaq:MPLT, MapLight Therapeutics, Inc., Schizophrenia, Alzheimer’s Disease Psychosis, Autism Spectrum Disorder, Biotechnology, Clinical Trials, Muscarinic